We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
0.43 | 0.34% | 125.49 | 126.23 | 124.71 | 126.23 | 4,038,523 | 20:37:05 |
By Colin Kellaher
Merck & Co. on Wednesday said the European Commission approved the expanded use of its cancer drug Keytruda in adults and children with relapsed or refractory classical Hodgkin lymphoma.
The Kenilworth, N.J., drugmaker said the approval covers Keytruda as a monotherapy for patients ages 3 and older who have failed autologous stem cell transplant or following at least two prior therapies when transplant isn't a treatment option.
Merck said the approval marks the first pediatric indication in the European Union for Keytruda, which harnesses a patient's immune system to fight tumors.
Classical Hodgkin lymphoma accounts for more than 90% of cases of Hodgkin lymphoma, a cancer of the lymphatic system, which is part of the immune system.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
March 17, 2021 07:32 ET (11:32 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions